A comparison of preferences for two GLP-1 products - Liraglutide and exenatide - For the treatment of type 2 diabetes

Journal of Medical Economics

Volumn 13, Issue 4, 2010, Pages 655-661

  Polster, Michael ^a   Zanutto, Elaine ^a   McDonald, Susan ^a   Conner, Christopher ^b   Hammer, Mette ^c  

^a National Analysts   (United States)

^b NOVO NORDISK INC   (United States)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Conjoint; Eenatide; GLP 1; Liraglutide; Time trade off

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE;

ADULT; ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG PREFERENCE; FEMALE; GLYCEMIC CONTROL; HEALTH SURVEY; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; QUESTIONNAIRE;

ADULT; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NAUSEA; PATIENT PREFERENCE; PEPTIDES; QUALITY OF LIFE; SOCIOECONOMIC FACTORS; VENOMS;

EID: 78650069893     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.529377     Document Type: Article

References (29)

1. Torrance GW, Thomas WH, Sackett D. A utility maximization model for evaluation of health care programs. Health Serv Res 1972;7:118-133
2. Torrance GW. Measurement of health state utilities for economic appraisal. A review. J Health Econ 1986;5:1-30
3. Academy of Managed Care Pharmacy. Format for Formulary Submissions (Version 3.0). Alexandria, VA, 2009
4. Chancellor J, Aballea S, Lawrence Al, et al. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 2008;26:217-234
5. Huang ES, Brown SES, Ewigman BG, et al. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care 2007;30:2478-2483
6. Peyrot M, Rubin RR. How does treatment satisfaction work? Diabetes Care 2009;32:1411-1417
7. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005;4:361-70
8. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008;31:1-11
9. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. National Institute for Health and Clinical Excellence, England (UK) 2004 (cited 2009 Jan 20) Available from: http:// www.nice.org. uk/niceMedia/pdf/TAP-Methods.pdf
10. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258
11. Brooks R, Rabin R, de Charro F. The measurement and valuation of health status using EQ-5D: a European perspective. Dordrecht: Kluwer Academic Publishers, 2003
12. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343
13. King JT, Styn MA, Tsevat J, et al. 'Perfect health' versus 'disease free': the impact of anchor point choice on the measurement of preferences and the calculation of disease-specific disutilities. Med Decis Making 2003;23:212-225
14. Wittrup-Jensen KU, Lauridsen J, Gudex C, et al. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health, 2009;37:459-466
15. Arnesen T, Trommald M. Are QALYs based on time trade-off comparable? - A systematic review of TTO methodologies. Health Econ 2004;14:39-53
16. Stiggelbout AM, Kiebert GM, Kievit J, et al. The 'utility' of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol 1995;48:1207-1214
17. Buse J, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
18. Rossi PE, Allenby GM, McCulloch R. Bayesian Statistics and Marketing. Marketing Science 2003;22:304-28
19. O'Brien B. Principles of economic evaluation for healthcare programs. J Rheumatol 1995;7:1399-1402
20. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-1265
21. Allenby GM, Rossi PE. Marketing models of consumer heterogeneity. J Econom 1999;89:57-78
22. Saydah SH, Fradkin, J, Cowie, CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-342
23. Clarke P, Gray A, Holman R. UKPDS 62. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D. Med Decis Making 2002; 22:340-349
24. Hunot VM, Horne R, Leese MN, et al. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. prim care companion. J Clin Psychiatry 2007;9:91-99
25. Raue PJ, Schulberg HC, Heo M, et al. Patient preferences for depression treatment and initiation, adherence, and outcome: a randomized study in primary care. Psychiatr Serv 2009;60:337-343
26. Brown GC, Brown MM, Sharma S, et al. Quality of live associated with diabetes mellitus in an adult population. J Diabetes Complications 2000; 14:18-24
27. Kahneman D, Tversky A. Prospect theory: an analysis of decision under risk. Econometrica 1979;47:263-292
28. Bleichrodt H, Pinto JL, Abellan-Perpinan JM. A consistency test of the time trade-off. J Health Econ 2003;22:1037-1052
29. Buckingham JK, Birdsall J, Douglas JG. Comparing three version of the time tradeoff: time for a change? Med Decis Making 1996;16:335-347